Previous attempts at glioma classification including by Verhaak et al. [5] did not carry over into the clinic even though they identified important associations, in part due to cost but also due to a lack of clear connection to other markers such as MGMT and IDH which are actively being measured in the clinic and, more significantly, because of a lack of connection to clinical features that define the outcome and clinical decision making in the real world. This evidence concerns the gene MGMT and central nervous system cancer.